Moderna’s Insider Trading During the Pandemic, so far!

Moderna (MRNA) insiders are busy selling their stock while promoting a promising vaccine

Andrea Piacquadio, Karolina Grabowska on pexels.comSee caption

Until May, it was a little-known biotech company. In just a few months, since it became a significant player in the hunt for a Covid-19 vaccine, Moderna has become a familiar stock to most traders across the market. Its vaccine candidate, mRNA-1273, and its CEO, Stephane Bancel are now relatively well known.